Ascentage Pharma Group International (FRA:36X)

FRA:36X Statistics

Total Valuation

FRA:36X has a market cap or net worth of EUR 2.59 billion. The enterprise value is 2.60 billion.

Market Cap	2.59B
Enterprise Value	2.60B

Important Dates

The last earnings date was Wednesday, November 19, 2025.

Earnings Date	Nov 19, 2025
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	368.05M
Shares Outstanding	n/a
Shares Change (YoY)	+12.40%
Shares Change (QoQ)	+9.35%
Owned by Insiders (%)	12.80%
Owned by Institutions (%)	16.29%
Float	282.52M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	55.77
PB Ratio	32.23
P/TBV Ratio	38.20
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-18.85
EV / Sales	54.94
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-100.75

Financial Position

The company has a current ratio of 1.54, with a Debt / Equity ratio of 2.54.

Current Ratio	1.54
Quick Ratio	1.40
Debt / Equity	2.54
Debt / EBITDA	n/a
Debt / FCF	-7.91
Interest Coverage	-19.26

Financial Efficiency

Return on equity (ROE) is -159.65% and return on invested capital (ROIC) is -28.78%.

Return on Equity (ROE)	-159.65%
Return on Assets (ROA)	-22.77%
Return on Invested Capital (ROIC)	-28.78%
Return on Capital Employed (ROCE)	-62.03%
Revenue Per Employee	76,740
Profits Per Employee	-227,743
Employee Count	567
Asset Turnover	0.13
Inventory Turnover	3.70

Taxes

In the past 12 months, FRA:36X has paid 1.89 million in taxes.

Income Tax	1.89M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +29.91% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	+29.91%
50-Day Moving Average	7.62
200-Day Moving Average	6.64
Relative Strength Index (RSI)	44.30
Average Volume (20 Days)	103

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, FRA:36X had revenue of EUR 46.43 million and -137.78 million in losses. Loss per share was -0.42.

Revenue	46.43M
Gross Profit	42.19M
Operating Income	-133.22M
Pretax Income	-135.91M
Net Income	-137.78M
EBITDA	-124.11M
EBIT	-133.22M
Loss Per Share	-0.42

Balance Sheet

The company has 197.48 million in cash and 203.99 million in debt, giving a net cash position of -6.50 million.

Cash & Cash Equivalents	197.48M
Total Debt	203.99M
Net Cash	-6.50M
Net Cash Per Share	n/a
Equity (Book Value)	80.34M
Book Value Per Share	0.23
Working Capital	79.57M

Cash Flow

In the last 12 months, operating cash flow was -22.48 million and capital expenditures -3.30 million, giving a free cash flow of -25.78 million.

Operating Cash Flow	-22.48M
Capital Expenditures	-3.30M
Free Cash Flow	-25.78M
FCF Per Share	n/a

Margins

Gross margin is 90.87%, with operating and profit margins of -286.93% and -296.77%.

Gross Margin	90.87%
Operating Margin	-286.93%
Pretax Margin	-292.74%
Profit Margin	-296.77%
EBITDA Margin	-267.32%
EBIT Margin	-286.93%
FCF Margin	n/a

Dividends & Yields

FRA:36X does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-12.40%
Shareholder Yield	-12.40%
Earnings Yield	-5.32%
FCF Yield	-1.00%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

FRA:36X has an Altman Z-Score of -0.62 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-0.62
Piotroski F-Score	3